<DOC>
	<DOCNO>NCT01922128</DOCNO>
	<brief_summary>Study evaluate safety tolerability MC-1101 , potential topical treatment non-edxudative age Related Macular Degeneration ( AMD ) medically stable individual .</brief_summary>
	<brief_title>Safety Study Topical Treatment Dry Age Related Macular Degeneration</brief_title>
	<detailed_description>MC-1101 topical version previously approve anti-hypertensive drug intend increase choroidal blood flow . - A reduction choroidal blood flow identify patient AMD - This study evaluate 0.5 % 1.0 % potency MC-1101 deliver 2X per day .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Geographic Atrophy</mesh_term>
	<criteria>1 . Subjects ≥ 50 ≤ 85 year age . 2 . Women must postmenopausal surgically sterilize 1 year longer . 3 . Best correct distance visual acuity 1.0 logMAR good eye ( 20/200 Snellen equivalent ) . 4 . Able willing sign inform consent HIPAA authorization , follow study instruction complete study visit . A study visit may require several exam course day . 5 . Able willing discontinue use ocular medication ( ) except artificial tear least one week prior receive study treatment entire course study . 6 . General good health , evaluate investigator , base medical history provide subject adjunctive testing carry investigator 's discretion . Ophthalmic : 1 . Previous intravitreal injection antiVEGF therapy either eye . 2 . History diabetes diabetic retinopathy &gt; 10 year . 3 . Ocular laser surgery either eye within 3 month Visit 1 . 4 . Ocular injection either eye medication within 3 month Visit 1 . 5 . History incisional glaucoma surgery either eye . 6 . Corneal , cataract medium opacification either eye limit adequate view fundus opinion investigator . 7 . Contraindications pupil dilation either eye . 8 . Any ocular disease require ongoing treatment topical ocular agent either eye study . Patients use intermittent ocular medication must stop medication one week prior Visit 2 . Use artificial tear 3 time daily less mild dry eye disease allow , must occur within ± 15 minute dose investigational product ) . 9 . Corneal disease , corneal irregularity scar opinion investigator would make difficult accurately measure intraocular pressure ( IOP ) visualize intraocular anatomy either eye . 10 . Presence HudsonStahli line corneal epithelium either eye . General/Systemic : 1 . Female subject menstruate . 2 . Prior participation ( participation define randomized investigational product ) study last 30 day . 3 . Subjects unable administer caretaker administer study eye drop . 4 . Subjects unable follow instruction unwilling consider physically unable return study visit duration study . 5 . Clinically significant systemic disease opinion investigator would interfere subject 's ability comply study requirement interpretation study result . 6 . Clinically significant abnormal result laboratory test , available investigator , investigator 's judgment would prohibit subject safe participation trial . 7 . Current past use ( 30 day ) chloroquine , hydroxychloroquine , chlorpromazine , thioridazine , quinine sulfate , clofazamine , cisplatin , carmustine , deferoxamine . 8 . Uncontrolled blood pressure systolic value ≥ 170 diastolic ≥ 100 mmHg . Repeated measurement allow investigator 's opinion time interval recent antihypertensive medication dose blood pressure measurement insufficient provide efficacious hypertension reduction . 9 . Subjects likely undergo change systemic medication . All medication take chronic basis must stable 30 day prior Visit 2 . Medications acute illness use within 30 day Visit 1 must discontinue prior randomization .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Non-exudative , dry AMD</keyword>
</DOC>